Methotrexate: A drug of the future in ulcerative colitis?

Current Drug Targets

Volumn 12, Issue 10, 2011, Pages 1413-1416

  Carbonnel, Franck ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Immunomodulators; Methotrexate; Therapy; Ulcerative colitis

Indexed keywords

CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PLACEBO; PREDNISONE;

ALLERGIC PNEUMONITIS; ALLERGY; ARTHRALGIA; ARTICLE; CHOLESTASIS; CHRONIC DISEASE; CLINICAL ASSESSMENT; ENTERITIS; HEART FAILURE; HUMAN; HYPERTENSION; INFLAMMATORY DISEASE; KIDNEY DISEASE; LEUKOPENIA; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MYALGIA; NAUSEA; PANCREATITIS; RHEUMATOID ARTHRITIS; SEIZURE; ULCERATIVE COLITIS;

CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; HUMANS; METHOTREXATE; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES;

EID: 80051705228     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011796818252     Document Type: Article

References (44)

1. Loftus AV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence and environmental factors. Gastroenterology 2004; 126: 1504-1517.
2. Thia KT, Loftus EV, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol 2008; 103: 3167-3182.
3. Faubion WA, Loftus EV, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-260.
4. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first ten years of ulcerative colitis: results from a population-based inception cohort (IBSEN study). Scand J Gastro 2009; 44: 431-440.
5. Travis S, Stange EF, Lemann M, et al. European evidence-based consensus on ulcerative colitis: current management. J Crohn Colitis 2008; 2: 24-62.
6. Kamm, M, Sandborn W, Gassull M, et al. Once daily high concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132: 66-75.
7. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on a controlled therapeutic trial. Br Med J 1974; 4: 627-630.
8. Caprilli R, Carratu R, Babbini M, et al. A double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis. Dig Dis Sci 1975; 20: 115-120.
9. Rosenberg JL, Wall AJ, Levin B, Binder HJ, Kirsner JB. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975; 69: 96-99.
10. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. BMJ 1982; 284: 1291-1292.
11. Hawthorne AB, Logan RFA, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305: 2022.
12. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006; 55: 47-53.
13. Vernier-Massouille G, Cosnes J, Lemann M, et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut 2007; 56: 1404-1409.
14. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproilferative disorders in patients receiving thiopurines for inflammatory bowel disease, a prospective observational cohort study. Lancet 2009; 374: 1617-1625.
15. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476.
16. Rheumatoid arthritis clinical trial archive group. The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. J Rheumatol 1995; 22: 218-223.
17. Khanna D, Park GS, Paulus HE, et al. Reduction of efficacy of methotrexate by the use of folic acid. Arthritis Rheum 2005; 52: 3030-3038.
18. Laharie D, Seneschal J, Schaeverbeke T, et al. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case control study. J Hepatol 2010; 53: 1035-1040.
19. Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002; 99: 3909-3915.
20. Visser K, Katchamart W, Loza E, et al. Multinational evidencebased recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009; 68: 1086-1093.
21. Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997; 36: 86-90.
22. Kurnik D, Loebstein R, Fishbein E, et al. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther 2003; 18: 57-63.
23. Balis FM, Mirro J Jr, Reaman GH, et al. Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol 1988; 6: 1882-1886.
24. Jundt JW, Browne BA, Fiocco GP, et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993; 20: 1845-1849.
25. Brooks PJ, Spruill WJ, Parish RC, et al. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33: 91-94.
26. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995 2; 332: 292-299.
27. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000; 342: 1627-1632.
28. Oren R, Moshkowitz M, Odes S, et al. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997; 92: 2203-2209.
29. Arora S, Katkov W, Cooley J, et al. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1999; 46: 1724-1729.
30. Dignass A, Van Assche G, Lindsey GO, et al. The second European evidence-based consensus on the diagnosis and managements of Crohn's disease: current management. J Crohn Colitis 2010; 4: 28-62.
31. http://www.snfge.org/data/FlashConfs/2006/048/
32. Kozarek RA, Patterson DJ, Botoman VA, Ball TJ, Gelfand MD. Methotrexate use in inflammatory bowel disease patients who have failed azathioprine or 6-mercaptopurine. Ann Int Med 1989; 110: 353-356.
33. Fraser AG, Morton D, McGovern D, Travis S, Jewell DP. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 693-697.
34. Paoluzi OA, Pica R, Marcheggiano A, et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther 2003; 16: 1751-1759.
35. Siveke JT, Folwaczny C. Methotrexate in ulcerative colitis. Aliment Pharmacol Ther 2003; 17: 479-480.
36. Soon SY, Ansari A, Yaneza M, et al. Experience with the use of low dose methotrexate for inflammatory bowel disease. Eur J Gastroenterol Hepatol 2004; 16: 921-926.
37. Cummings JRF, Herrlinger KR, Travis SPL et al. Oral methotrexate in ulcerative colitis. Aliment Pharmacol Ther 2005; 21: 385-389.
38. Nathan DM, Iser JH, Gibson PR. A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration. J Gastroenterol Hepatol 2008; 23: 954-958.
39. Wahed M, Louis-Auguste JR, Baxter LM, et al. Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine/mercaptopurine. Aliment Pharmacol Ther 2009; 30: 614-620.
40. Aloi M, Di Nardo G, Conte F, et al. Methotrexate in pediatric ulcerative colitis, a retrospective survey at a single tertiary referral center. Alim Pharm Ther 2010; 32(8): 1017-1022.
41. Oren R, Arber N, Odes S, et al. Methotrexate in chonic active ulcerative colitis: a double blind randomized israeli multicenter trial. Gastroenterology 1996; 110: 1416-1421.
42. Maté-Jiménez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6- mercaptopurine or methotrexate added to prenisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12: 1227-1233.
43. Egan LJ, Sandborn WJ, Tremaine WJ, et al. A randomized dose response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 1597-1604.
44. Herfarth HH, Osterman MT, Isaacs KL, Lewis JD, Sands BE. Efficacy of methotrexate in ulcerative colitis: failure or promise. Infl Bowel Dis 2010; 16: 1421-1430.